Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

Soledad Herrero; Yolanda Pico

doi:10.1016/j.ejphar.2016.02.053

Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

Eur J Pharmacol. 2016 May 15:779:8-21. doi: 10.1016/j.ejphar.2016.02.053. Epub 2016 Feb 26.

Authors

Soledad Herrero¹, Yolanda Pico²

Affiliations

¹ Food and Environmental Research Group (SAMA-UV), Department of Preventive Medicine, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, Burjassot 46100, València, Spain. Electronic address: sohero@hotmail.com.
² Food and Environmental Research Group (SAMA-UV), Department of Preventive Medicine, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, Burjassot 46100, València, Spain.

PMID: 26923729
DOI: 10.1016/j.ejphar.2016.02.053

Abstract

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopausal women (PMW), paying particular attention to long-term treatments.

Keywords: Bisphosphonate; Cathepsin K; Denosumab; Long-term-Treatment; Postmenopausal Osteoporosis; Romosozumab.

Publication types

Review

MeSH terms

Female
Humans
Osteoporosis, Postmenopausal / drug therapy*
Time Factors